Bruker (BRKRP) Cash & Equivalents (2009 - 2026)

Bruker has reported Cash & Equivalents for 18 years, with the latest figure at $133.4 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 27.58% year-over-year to $133.4 million; the trailing twelve-month figure through Mar 2026 stood at $133.4 million (down 27.58% YoY), and the FY2025 full-year result was $298.8 million, up 62.92% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $133.4 million, down from $298.8 million in the prior quarter.
• The five-year high for Cash & Equivalents was $816.1 million in Q1 2022, with the low at $92.0 million in Q2 2025.
• Historically, Cash & Equivalents has averaged $392.8 million across 5 years, with a median of $340.1 million in 2024.
• Annual changes were most pronounced in 2024 — Cash & Equivalents sank 70.48% — and 2025, when it soared 97.91%.
• Bruker's Cash & Equivalents stood at $645.5 million in 2022, then retreated by 24.35% to $488.3 million in 2023, then sank by 62.44% to $183.4 million in 2024, then jumped by 62.92% to $298.8 million in 2025, then tumbled by 55.35% to $133.4 million in 2026.
• The last three Cash & Equivalents figures came in at $133.4 million (Q1 2026), $298.8 million (Q4 2025), and $293.1 million (Q3 2025), per Business Quant data.